The FDA has approved Pfizer and Astellas’ Padcev (enfortumab vedotin-ejfv) plus Merck’s Keytruda (pembrolizumab) as a perioperative treatment for adults with muscle-invasive bladder cancer who are ...
The U.S. Food and Drug Administration (FDA) on Friday approved injectable and intravenous versions of Merck’s (MRK) ...
The Food and Drug Administration approved Merck's Keytruda in combination with Padcev to treat certain adults with muscle invasive bladder cancer (MIBC).
Discover why Pfizer stock may be set for a bull run by 2026 with key wins, strong Q3 earnings, and growth drivers.
(TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (R) (enfortumab vedotin-ejfv), a Nectin-4 directed ...
Pharma companies are spending billions on a treatment based off old drugs, with little evidence it will extend lives.
The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems to help fight tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback